• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic renal cell carcinoma disease response in the era of immune checkpoint inhibitor-based combinations.

作者信息

Ostrowski Micah, Gebrael Georges, Maughan Benjamin L

机构信息

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

出版信息

Transl Androl Urol. 2025 May 30;14(5):1169-1173. doi: 10.21037/tau-2025-93. Epub 2025 May 27.

DOI:10.21037/tau-2025-93
PMID:40529030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170065/
Abstract
摘要

相似文献

1
Metastatic renal cell carcinoma disease response in the era of immune checkpoint inhibitor-based combinations.基于免疫检查点抑制剂联合治疗时代的转移性肾细胞癌疾病反应
Transl Androl Urol. 2025 May 30;14(5):1169-1173. doi: 10.21037/tau-2025-93. Epub 2025 May 27.
2
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment.用于透明细胞肾细胞癌治疗的生物靶向双重适应性和先天性纳米免疫疗法。
Mol Cancer. 2025 Jun 18;24(1):181. doi: 10.1186/s12943-025-02382-y.
3
Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.评估从细胞因子前时代到免疫检查点抑制剂时代转移性肾细胞癌系统治疗的改善：真实世界数据的回顾性分析。
Jpn J Clin Oncol. 2021 Apr 30;51(5):793-801. doi: 10.1093/jjco/hyaa232.
4
Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.免疫检查点抑制剂在头颈部鳞状细胞癌中的应用：现状与未来展望。
Future Oncol. 2024;20(23):1695-1711. doi: 10.1080/14796694.2024.2362612. Epub 2024 Jun 18.
5
Comparison of Partial Nephrectomy Versus Radical Nephrectomy for Metastatic Renal Cell Carcinoma in the Immunotherapy Era: A Propensity Score Matching, Population-Based Analysis.免疫治疗时代转移性肾细胞癌行部分肾切除术与根治性肾切除术的比较：一项倾向评分匹配的基于人群的分析
Ann Surg Oncol. 2025 Jun 19. doi: 10.1245/s10434-025-17642-w.
6
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.从分子靶向治疗时代到免疫检查点抑制剂时代转移性肾细胞癌患者真实世界结局的变化。
Target Oncol. 2022 May;17(3):307-319. doi: 10.1007/s11523-022-00879-w. Epub 2022 Apr 23.
7
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.一线免疫治疗方案治疗转移性肾细胞癌的决定因素：近期证据的批判性综述。
Immunotherapy. 2021 Jun;13(8):685-692. doi: 10.2217/imt-2020-0323. Epub 2021 Apr 7.
8
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.一线免疫检查点抑制剂联合治疗时代的治疗序贯策略，转移性透明细胞肾细胞癌患者面临的新挑战。
Bull Cancer. 2022 May;109(2S):2S31-2S38. doi: 10.1016/S0007-4551(22)00236-3.
9
Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.免疫检查点抑制剂时代转移性肾细胞癌患者总生存的变化。
Cancer Epidemiol. 2024 Oct;92:102639. doi: 10.1016/j.canep.2024.102639. Epub 2024 Aug 14.
10
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.一线免疫治疗联合治疗后转移性透明细胞肾细胞癌二线治疗的无进展生存期。
Eur Urol. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017. Epub 2022 Nov 4.

本文引用的文献

1
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：III 期 CheckMate 214 试验疗效和安全性的 8 年扩展随访结果。
Ann Oncol. 2024 Nov;35(11):1026-1038. doi: 10.1016/j.annonc.2024.07.727. Epub 2024 Aug 2.
2
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.CLEAR 研究最终预设生存分析中晚期肾细胞癌患者接受仑伐替尼联合帕博利珠单抗治疗的反应特征。
Eur Urol. 2024 Jul;86(1):4-9. doi: 10.1016/j.eururo.2024.03.015. Epub 2024 Apr 6.
3
Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.免疫检查点抑制剂：iRECIST、irRC 和 irRECIST 的性能评估和一致性。
J Cancer Res Ther. 2024 Jan 1;20(1):156-162. doi: 10.4103/jcrt.jcrt_1898_22. Epub 2023 Apr 7.
4
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.免疫检查点抑制剂时代的细胞减灭性肾切除术：美国食品和药物管理局的汇总分析。
J Natl Cancer Inst. 2024 Jul 1;116(7):1043-1050. doi: 10.1093/jnci/djae066.
5
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.仑伐替尼联合帕博利珠单抗对比舒尼替尼用于晚期肾细胞癌一线治疗：CLEAR 研究的最终预设总生存分析，一项 III 期研究。
J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16.
6
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.先前细胞减灭性肾切除术对阿维鲁单抗联合阿昔替尼或舒尼替尼治疗同步转移性肾细胞癌患者疗效的影响：来自 JAVELIN Renal 101 期 3 试验的事后分析。
Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16.
7
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.舒尼替尼对比干扰素-α治疗转移性肾细胞癌患者的总生存期和更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1965-1971. doi: 10.1200/JCO.22.02623.
8
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience.立体定向体部放疗与姑息性放疗对同时接受免疫检查点抑制剂治疗的转移性肾细胞癌患者肿瘤学结局的影响：初步的多中心经验。
Clin Transl Oncol. 2022 Oct;24(10):2039-2043. doi: 10.1007/s12094-022-02844-5. Epub 2022 Jun 23.
9
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.纳武利尤单抗联合卡博替尼与舒尼替尼用于晚期肾细胞癌一线治疗（CheckMate 9ER）：一项开放标签、随机、III 期临床试验的长期随访结果。
Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7.
10
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.转移性透明细胞肾细胞癌的一线治疗：不断扩大的领域。
Oncologist. 2022 Mar 4;27(2):125-134. doi: 10.1093/oncolo/oyab056.